HK1202157A1 - 用於預測未接受他汀藥物治療的冠狀動脈疾病患者的心血管後果的脂質組學生物標誌 - Google Patents
用於預測未接受他汀藥物治療的冠狀動脈疾病患者的心血管後果的脂質組學生物標誌Info
- Publication number
- HK1202157A1 HK1202157A1 HK15102644.9A HK15102644A HK1202157A1 HK 1202157 A1 HK1202157 A1 HK 1202157A1 HK 15102644 A HK15102644 A HK 15102644A HK 1202157 A1 HK1202157 A1 HK 1202157A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- prediction
- coronary artery
- artery disease
- disease patients
- statin treatment
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161556909P | 2011-11-08 | 2011-11-08 | |
| EP11188328.6A EP2592423A1 (en) | 2011-11-08 | 2011-11-08 | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
| PCT/EP2012/071972 WO2013068373A2 (en) | 2011-11-08 | 2012-11-07 | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1202157A1 true HK1202157A1 (zh) | 2015-09-18 |
Family
ID=45033777
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15102644.9A HK1202157A1 (zh) | 2011-11-08 | 2015-03-16 | 用於預測未接受他汀藥物治療的冠狀動脈疾病患者的心血管後果的脂質組學生物標誌 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9052328B2 (zh) |
| EP (3) | EP2592423A1 (zh) |
| JP (1) | JP6388283B2 (zh) |
| CN (1) | CN103917876B (zh) |
| CA (1) | CA2853220A1 (zh) |
| HK (1) | HK1202157A1 (zh) |
| WO (1) | WO2013068373A2 (zh) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2592422A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment |
| EP2592423A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
| ES2552371T3 (es) * | 2012-05-25 | 2015-11-27 | Zora Biosciences Oy | Biomarcadores sensibles, eficaces e inocuos, para la inhibición de la Proproteína Convertasa Subtilisina/Kexina de tipo 9 (PCSK9) |
| CA2926592A1 (en) * | 2013-11-14 | 2015-05-21 | Nestec S.A. | Lipid biomarkers of healthy ageing |
| AU2014389998B2 (en) | 2014-04-10 | 2019-10-31 | MEP Equine Solutions LLC | Method for the quantification of parasite eggs in feces |
| US9347960B2 (en) | 2014-06-16 | 2016-05-24 | Zora Biosciences, Oy | Ceramides and their use in diagnosing CVD |
| WO2016040859A1 (en) * | 2014-09-11 | 2016-03-17 | Liposcience Inc. | Cardiovascular risk evaluations using a risk parameter that includes an hdl and inflammatory biomarker interaction parameter |
| WO2016100549A2 (en) | 2014-12-16 | 2016-06-23 | Washington University | Ceramides for evaluating risk of cardiovascular disease |
| WO2017029401A1 (en) * | 2015-08-19 | 2017-02-23 | Metanomics Gmbh | Means and methods for diagnosing cardiac disease in a subject |
| ES2861401T3 (es) * | 2015-10-20 | 2021-10-06 | Medimmune Llc | Marcador de diagnóstico para arteriopatía coronaria |
| US10184932B2 (en) | 2015-12-07 | 2019-01-22 | Zora Biosciences Oy | Use of ceramides and LPLs in diagnosing CVD |
| CN105424841B (zh) * | 2015-12-25 | 2017-11-03 | 齐炼文 | 用于诊断冠状动脉粥样硬化的代谢标志物 |
| CN107014942A (zh) * | 2017-05-05 | 2017-08-04 | 北京骐骥生物技术有限公司 | 利用脂质生物标志物预测糖尿病冠心病的方法 |
| CN107144624B (zh) * | 2017-05-15 | 2021-01-05 | 中国科学院生态环境研究中心 | 甄别二氧化硅颗粒来源的方法 |
| CN108037275A (zh) * | 2017-12-14 | 2018-05-15 | 北京豪思生物科技有限公司 | 一种用于评估冠状动脉疾病的试剂盒 |
| WO2019119049A1 (en) * | 2017-12-20 | 2019-06-27 | Baker Heart and Diabetes Institute | Method of predicting drug therapeutic responder status and methods of treatment |
| CA3122035A1 (en) | 2018-12-06 | 2020-06-11 | Zora Biosciences Oy | Biomarkers for cardiovascular events |
| CN113533754A (zh) * | 2021-07-12 | 2021-10-22 | 北京市心肺血管疾病研究所 | 神经酰胺在制备用于评估高血压患者发生不良事件风险的试剂盒中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7590198A (en) * | 1997-06-10 | 1998-12-30 | Medlyte Diagnostics, Inc. | Methods for early detection of heart disease |
| AU2003286726A1 (en) | 2002-10-25 | 2004-05-13 | Metabolon, Inc. | Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| GB0517878D0 (en) * | 2005-09-02 | 2005-10-12 | Bioinvent Int Ab | Immunotherapeutic treatment |
| US7972802B2 (en) | 2005-10-31 | 2011-07-05 | University Of Washington | Lipoprotein-associated markers for cardiovascular disease |
| US8137977B2 (en) * | 2006-04-24 | 2012-03-20 | Children's Hospital & Research Center At Oakland | Lipidomic approaches to determining drug response phenotypes in cardiovascular disease |
| DE102006034153B4 (de) | 2006-07-24 | 2018-02-08 | Magna powertrain gmbh & co kg | Getriebe |
| WO2008148857A1 (en) | 2007-06-07 | 2008-12-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for assessing the risk of a cardiovascular disease and for diagnosing dyslipidemia |
| BR122018070240B1 (pt) * | 2007-06-08 | 2019-07-09 | Quest Diagnostics Investments Incorporated | Processo para análise da distribuição de tamanhos de lipoproteínas |
| EP2048243A1 (en) | 2007-09-24 | 2009-04-15 | sanofi-aventis | Use of clec1B for the determination of cardiovascular and thrombotic risk |
| EP2247775B1 (en) | 2008-01-28 | 2012-12-19 | National University of Singapore | Method of generating a classification model |
| CN101977933A (zh) | 2008-03-12 | 2011-02-16 | 奥塔哥创新有限公司 | 生物标记物 |
| JP5749171B2 (ja) | 2008-10-30 | 2015-07-15 | ルクセンブルグ・インスティテュート・オブ・ヘルス | バイオマーカー |
| US20110034419A1 (en) * | 2009-06-27 | 2011-02-10 | Musc Foundation For Research Development | Cardioprotective Drugs and Diagnostics for Assessing Risk of Cardiovascular Disease |
| US9066939B2 (en) * | 2009-11-17 | 2015-06-30 | Baylor Research Institute | Urinary triaosylceramide (GB3) as a marker of cardiac disease |
| ES2665621T3 (es) | 2009-11-27 | 2018-04-26 | Baker Idi Heart And Diabetes Institute Holdings Ltd | Biomarcadores lipidómicos para la enfermedad cardiaca estable e inestable |
| ES2455124T5 (es) | 2010-05-05 | 2018-05-08 | Zora Biosciences Oy | Biomarcadores lipidómicos para la aterosclerosis y afección cardíaca |
| CN103154742B (zh) | 2010-06-20 | 2017-11-21 | 佐拉生物科学公司 | 用于鉴定高风险冠状动脉疾病患者的脂质组学标志 |
| US9664698B2 (en) | 2011-04-08 | 2017-05-30 | Zora Biosciences Oy | Biomarkers for sensitive detection of statin-induced muscle toxicity |
| EP2592423A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
| EP2592422A1 (en) | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment |
-
2011
- 2011-11-08 EP EP11188328.6A patent/EP2592423A1/en not_active Withdrawn
-
2012
- 2012-11-07 WO PCT/EP2012/071972 patent/WO2013068373A2/en active Application Filing
- 2012-11-07 EP EP12781324.4A patent/EP2776841B1/en active Active
- 2012-11-07 CA CA2853220A patent/CA2853220A1/en not_active Abandoned
- 2012-11-07 CN CN201280054323.8A patent/CN103917876B/zh active Active
- 2012-11-07 US US14/356,594 patent/US9052328B2/en active Active
- 2012-11-07 EP EP17150693.4A patent/EP3208617B1/en active Active
- 2012-11-07 JP JP2014540426A patent/JP6388283B2/ja active Active
-
2015
- 2015-03-16 HK HK15102644.9A patent/HK1202157A1/zh unknown
- 2015-05-27 US US14/722,964 patent/US9423406B2/en active Active
-
2016
- 2016-07-14 US US15/210,048 patent/US9863965B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2592423A1 (en) | 2013-05-15 |
| EP3208617B1 (en) | 2021-02-24 |
| US20160320418A1 (en) | 2016-11-03 |
| US9052328B2 (en) | 2015-06-09 |
| US9423406B2 (en) | 2016-08-23 |
| EP2776841B1 (en) | 2017-01-11 |
| CN103917876B (zh) | 2018-02-02 |
| US20150260737A1 (en) | 2015-09-17 |
| WO2013068373A2 (en) | 2013-05-16 |
| JP6388283B2 (ja) | 2018-09-12 |
| EP3208617A3 (en) | 2017-11-01 |
| CA2853220A1 (en) | 2013-05-16 |
| EP3208617A2 (en) | 2017-08-23 |
| US20140295467A1 (en) | 2014-10-02 |
| WO2013068373A3 (en) | 2013-07-18 |
| US9863965B2 (en) | 2018-01-09 |
| EP2776841A2 (en) | 2014-09-17 |
| JP2014532885A (ja) | 2014-12-08 |
| CN103917876A (zh) | 2014-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1202154A1 (zh) | 用於預測接受他汀藥物治療的冠狀動脈疾病患者的心血管後果的脂質組學生物標誌 | |
| HK1202157A1 (zh) | 用於預測未接受他汀藥物治療的冠狀動脈疾病患者的心血管後果的脂質組學生物標誌 | |
| PT2619576T (pt) | Meios e métodos para a previsão de resposta ao tratamento de um paciente com cancro | |
| EP2686007A4 (en) | METHOD FOR THE DIAGNOSIS AND TREATMENT OF VASCULAR MACULOPATHY AND SYMPTOMS THEREOF | |
| HK1198556A1 (zh) | 慢性阻塞性肺疾病患者的結果的預測 | |
| EP2529033A4 (en) | METHOD AND COMPOSITIONS FOR RISK OVERVIEW, DIAGNOSIS, FORECASTING AND TREATMENT OF LUNG DISEASES | |
| EP2668504A4 (en) | PREDICTIVE TEST FOR SELECTING PATIENTS WITH METASTATIC BREAST CANCERS TO RECEIVE HORMONE THERAPY AND POLY THERAPY | |
| IL222844A0 (en) | Biomarkers for the treatment of psoriasis | |
| SG11201400919RA (en) | Patient stratification and determining clinical outcome for cancer patients | |
| GB2496688B (en) | Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases | |
| IL223310A0 (en) | Apple skin extracts for treating cardiovascular disease | |
| EP2709618A4 (en) | METHOD FOR THE TREATMENT AND DIAGNOSIS OF PULMONARY ARTERIAL HYPERTENSION | |
| EP2557920A4 (en) | METHODS FOR THE TREATMENT OF GLUCOSE METABOLISM DISORDERS | |
| ZA201307905B (en) | Use of fk506 for the treatment of pulmonary arterial hypertension | |
| HK1257401A1 (zh) | 用於治療糖尿病和相關病症的方法和組合物 | |
| PT2807486T (pt) | Método para a previsão in vitro, numa amostra sanguínea, da probabilidade de um paciente desenvolver dengue grave | |
| GB201101959D0 (en) | Novel ether linked compoundsand improved treatments for cardiac and cardiovascular disease | |
| EP2755671A4 (en) | COMBINATION OF PTEROSTILS AND STATINE FOR THE TREATMENT OF METABOLISM DISEASES, CARDIOVASCULAR DISEASES AND INFLAMMATION | |
| IL228891A (en) | 3-carboxylic salts-n-ethyl n, n-dimethylpropane-1-amine for use in the treatment of cardiovascular disease | |
| EP2528612A4 (en) | METHODS OF TREATING GLUCOSE METABOLISM DISORDERS | |
| GB201218050D0 (en) | Inhibitors of glucose metabolism for use in the treatment of birt-hogg-dube syndrome | |
| EP2528614A4 (en) | METHODS OF TREATING GLUCOSE METABOLISM DISORDERS | |
| EP2523730A4 (en) | METHOD FOR THE TREATMENT OF GLUCOSE TISSUE CHANGES | |
| EP2820426A4 (en) | NOVEL TARGET MOLECULE FOR THE DIAGNOSIS AND TREATMENT OF DIABETES AND HEART CIRCULAR DISEASES | |
| EP2721410A4 (en) | BIOMARKERS FOR THE DIAGNOSIS AND TREATMENT OF EPITHELIAL CANCER |